Intranasal ketamine

The Essence of Analgesia and Analgesics

Volumn , Issue , 2010, Pages 440-443

  Carr, Daniel B ^a,b   Lanier, Ryan ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b Javelin Pharmaceuticals Inc   (United States)

^c Rock Creek Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85012141601     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511841378.110     Document Type: Chapter

References (5)

1. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982; 56: 119-136.
2. Tucker AP, Kim YI, Nadeson R, Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomized, placebo controlled crossover study of experimental pain. BioMed Central Anesthesiol 2005;5:2.
3. Christensen K, Rogers E, Green GA, Hamilton DA, Mermelstein F, Liao E, Wright C, Carr DB. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain 2007; 9: 183-192.
4. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004; 108: 17-27.
5. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacol 2006;60:341-348.